1. Proceedings
  2. I3M
  3. 2019
  4. IWISH
  5. 10.46354/i3m.2019.iwish.017

Strategies for nose-to-brain drug delivery

  • a Rodrigo Quispe  , 
  • b Jorge A. Trevino  , 
  • c Faizan Khan  , 
  • d Vera Novak 
  • a,b,c,dDepartment of Neurology, SAFE Laboratory, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Cite as
Quispe R. C., Trevino J. A., Khan F., Novak V. (2019). Strategies for nose-to-brain drug delivery. Proceedings of the 8th International Workshop on Innovative Simulation for Healthcare (IWISH 2019), pp. 96-108. DOI: https://doi.org/10.46354/i3m.2019.iwish.017

Abstract

Intranasal drug administration is an effective method that has shown promise for delivering drugs directly to the brain. This approach is associated with many challenges, and efficacy in bypassing blood-brain barrier (BBB) is debated. This review describes the pathways of nose-to-brain drug delivery, physicochemical drug properties that influence drug uptake through the nasal epithelium, physiological barriers, methods to enhance nose-to-brain absorption, drug bioavailability and biodistribution, and intranasal devices for nose-to-brain drug delivery. The mechanism of each device is described and supporting evidence from clinical trials is presented. This paper summarizes strategies involved in nose-to-brain drug delivery and provides evidence of potential efficacy of nose-braindelivery from clinical trials.

Intranasal | Nose-to-brain | Bioavailability | Biodistribution | Devices | Nebulizers

References

  1. “Acute Treatment Trial in Adult Subjects With Migraines - Full Text View - ClinicalTrials.Gov.” n.d. Accessed July 21, 2019. https://clinicaltrials.gov/ct2/show/NCT03872453. ClinicalTrials.gov Identifier: NCT03872453
  2. Akintola, Abimbola A., Anna M. van Opstal, Rudi G. Westendorp, Iris Postmus, Jeroen van der
    Grond, and Diana van Heemst. 2017. “Effect of Intranasally Administered Insulin on
    Cerebral Blood Flow and Perfusion; a Randomized Experiment in Young and Older Adults.” Aging (Albany NY) 9 (3): 790–802. https://doi.org/10.18632/aging.101192
  3. Benedict, Christian, Manfred Hallschmid, Bernd Schultes, Jan Born, and Werner Kern. 2007.
    “Intranasal Insulin to Improve Memory Function in Humans.” Neuroendocrinology
    86 (2): 136–42 https://doi.org/10.1159/000106378.
  4. Bhise, SatishBalakrishna, Adhikrao Vyankatrao Yadav, AmeliaMakrand Avachat, and
    Rajkumar Malayandi. 2008. “Bioavailability of Intranasal Drug Delivery System.” Asian
    Journal of Pharmaceutics 2 (4): 201. https://doi.org/10.4103/0973-8398.45032.
  5. Bitter, Christoph, Katja Suter-Zimmermann, and Christian Surber. 2011. “Nasal Drug Delivery
    in Humans.” Current Problems in Dermatology 40: 20–35. https://doi.org/10.1159/000321044
  6. Born, Jan, Tanja Lange, Werner Kern, Gerard P. McGregor, Ulrich Bickel, and Horst L. Fehm.
    2002. “Sniffing Neuropeptides: A Transnasal Approach to the Human Brain.” Nature
    Neuroscience 5 (6): 514–16. https://doi.org/10.1038/nn849.
  7. Brünner, Yvonne F., Rea Rodriguez-Raecke, Smiljana Mutic, Christian Benedict, and
    Jessica Freiherr. 2016. “Neural Correlates of Olfactory and Visual Memory Performance in
    3D-Simulated Mazes after Intranasal Insulin Application.” Neurobiology of Learning and
    Memory 134 Pt B: 256–63. https://doi.org/10.1016/j.nlm.2016.07.027.
  8. Chou, Kang-Jye, and Maureen D Donovan. 1998. “The Distribution of Local Anesthetics into
    the CSF Following Intranasal Administration.” International Journal of Pharmaceutics 168 (2): 137–45. https://doi.org/10.1016/S0378-5173(98)00061-1.
  9. Craft, Suzanne, Laura D. Baker, Thomas J. Montine, Satoshi Minoshima, G. Stennis
    Watson, Amy Claxton, Matthew Arbuckle, et al. 2012. “Intranasal Insulin Therapy for
    Alzheimer Disease and Amnestic Mild Cognitive Impairment.” Archives of
    Neurology 69 (1): 29–38. https://doi.org/10.1001/archneurol.2011.233.
  10. Craft, Suzanne, Amy Claxton, Laura D. Baker, Angela J. Hanson, Brenna Cholerton, Emily
    H. Trittschuh, Deborah Dahl, et al. n.d. “Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer’s Disease Biomarkers: A Pilot Clinical Trial.” Journal of Alzheimer’s Disease 57 (4): 1325–34. https://doi.org/10.3233/JAD-161256.
  11. Crowe, Tyler P., M. Heather West Greenlee, Anumantha G. Kanthasamy, and Walter H.
    Hsu. 2018. “Mechanism of Intranasal Drug Delivery Directly to the Brain.” Life Sciences
    195 (February): 44–52. https://doi.org/10.1016/j.lfs.2017.12.025.
  12. Crowe, Tyler P., M. Heather West Greenlee, Anumantha G. Kanthasamy, and Walter H.
    Hsu. 2018. “Mechanism of Intranasal Drug Delivery Directly to the Brain.” Life Sciences
    195 (February): 44–52. https://doi.org/10.1016/j.lfs.2017.12.025.
  13. Dale, Ola, Turid Nilsen, Thorsteinn Loftsson, Hanne Hjorth Tønnesen, Pål Klepstad, Stein
    Kaasa, Trond Holand, and Per G. Djupesland. 2006. “Intranasal Midazolam: A Comparison
    of Two Delivery Devices in Human Volunteers.” The Journal of Pharmacy and
    Pharmacology 58 (10): 1311–18. https://doi.org/10.1211/jpp.58.10.0003
  14. Dash, Satya, Changting Xiao, Cecilia Morgantini, Khajag Koulajian, and Gary F. Lewis. 2015.
    “Intranasal Insulin Suppresses Endogenous Glucose Production in Humans Compared
    with Placebo in the Presence of Similar Venous Insulin Concentrations.” Diabetes 64 (3): 766–74. https://doi.org/10.2337/db14- 0685.
  15. Dhuria, Shyeilla V., Leah R. Hanson, and William H. Frey. 2010. “Intranasal Delivery to the
    Central Nervous System: Mechanisms and Experimental Considerations.” Journal of
    Pharmaceutical Sciences 99 (4): 1654–73. https://doi.org/10.1002/jps.21924.
  16. Djupesland, P. G., P. Docekal, and Czech Migraine Investigators Group. 2010. “Intranasal
    Sumatriptan Powder Delivered by a Novel Breath-Actuated Bi-Directional Device for the
    Acute Treatment of Migraine: A Randomised, Placebo-Controlled Study.” Cephalalgia: An
    International Journal of Headache 30 (8): 933–42.
  17. Djupesland, Per Gisle. 2013. “Nasal Drug Delivery Devices: Characteristics and Performance in a
    Clinical Perspective—a Review.” Drug Delivery and Translational Research 3 (1):
    42–62. https://doi.org/10.1007/s13346-012-0108-9.
  18. Djupesland, Per Gisle, Arne Skretting, Mette Winderen, and Trond Holand. 2004. “Bi-
    Directional Nasal Delivery of Aerosols Can Prevent Lung Deposition.” Journal of Aerosol
    Medicine: The Official Journal of the International Society for Aerosols in Medicine
    17 (3): 249–59. https://doi.org/10.1089/jam.2004.17.249.
  19. Djupesland, PerGisle, Arne Skretting, Mette Winderen, and Trond Holand. 2006. “Breath
    Actuated Device Improves Delivery to Target Sites beyond the Nasal Valve.” The
    Laryngoscope 116 (3): 466–72. https://doi.org/10.1097/01.MLG.0000199741.
    08517.99.
  20. Erdő, Franciska, Luca Anna Bors, Dániel Farkas, Ágnes Bajza, and Sveinbjörn Gizurarson 2018. “Evaluation of Intranasal Delivery Route of Drug Administration for Brain Targeting.” Brain Research Bulletin 143: 155–70. https://doi.org/10.1016/j.brainresbull.2018.10. 009.
  21. Fehm, H. L., B. Perras, R. Smolnik, W. Kern, and J. Born. 2000. “Manipulating
    Neuropeptidergic Pathways in Humans: A Novel Approach to Neuropharmacology?”
    European Journal of Pharmacology 405 (1– 3): 43–54. https://doi.org/10.1016/s0014-
    2999(00)00540-9.
  22. Gänger, Stella, and Katharina Schindowski. 2018. “Tailoring Formulations for Intranasal Noseto-
    Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa.” Pharmaceutics 10 (3).
    https://doi.org/10.3390/pharmaceutics100301 16.
  23. Guthoff, Martina, Yuko Grichisch, Carlos Canova, Otto Tschritter, Ralf Veit, Manfred
    Hallschmid, Hans-Ulrich Häring, Hubert Preissl, Anita M. Hennige, and Andreas
    Fritsche. 2010. “Insulin Modulates Food- Related Activity in the Central Nervous
    System.” The Journal of Clinical Endocrinology and Metabolism 95 (2): 748–55. https://doi.org/10.1210/jc.2009-1677.
  24. Hallschmid, Manfred, Christian Benedict, Bernd Schultes, Boris Perras, Horst-Lorenz Fehm,
    Werner Kern, and Jan Born. 2008. “Towards the Therapeutic Use of Intranasal
    Neuropeptide Administration in Metabolic and Cognitive Disorders.” Regulatory
    Peptides 149 (1–3): 79–83. https://doi.org/10.1016/j.regpep.2007.06.012
  25. Hinchcliffe, null, and null Illum. 1999. “Intranasal Insulin Delivery and Therapy.” Advanced
    Drug Delivery Reviews 35 (2–3): 199–234.
  26. Hoekman, John D., Michael Hite, Alan Brunelle, Joel Relethford, and Rodney J. Y. Ho. 2017.
    Nasal drug delivery device. United States US20170043109A1, filed October 28, 2016,
    and issued February 16, 2017. https://patents.google.com/patent/US2017004
    3109A1/en?q=precision&q=olfactory&q=deli very&assignee=impel+neuropharma&oq=pre
    cision+olfactory+delivery+impel+neurophar ma.
  27. Illum, Lisbeth. 2000. “Transport of Drugs from the Nasal Cavity to the Central Nervous System.”
    European Journal of Pharmaceutical Sciences 11 (1): 1–18. https://doi.org/10.1016/S0928-
    0987(00)00087-7.
  28. Jauch-Chara, Kamila, Alexia Friedrich, Magdalena Rezmer, Uwe H. Melchert, Harald G.
    Scholand-Engler, Manfred Hallschmid, and Kerstin M. Oltmanns. 2012. “Intranasal
    Insulin Suppresses Food Intake via Enhancement of Brain Energy Levels in Humans.” Diabetes 61 (9): 2261–68. https://doi.org/10.2337/db12-0025.
  29. Jintapattanakit, Anchalee, Penchom Peungvicha, Achariya Sailasuta, Thomas Kissel, and
    Varaporn Buraphacheep Junyaprasert. 2010. “Nasal Absorption and Local Tissue Reaction
    of Insulin Nanocomplexes of Trimethyl Chitosan Derivatives in Rats.” The Journal of
    Pharmacy and Pharmacology 62 (5): 583– 91. https://doi.org/10.1211/jpp.62.05.0004
  30. Kamei, Noriyasu, Nobuyuki Okada, Takamasa Ikeda, Hayoung Choi, Yui Fujiwara, Haruka
    Okumura, and Mariko Takeda-Morishita. 2018. “Effective Nose-to-Brain Delivery of
    Exendin-4 via Coadministration with Cell- Penetrating Peptides for Improving
    Progressive Cognitive Dysfunction.” Scientific Reports 8 (December). https://doi.org/10.1038/s41598-018-36210-9.
  31. Kozlovskaya, Luba, Mohammed Abou-Kaoud, and  David Stepensky. 2014. “Quantitative
    Analysis of Drug Delivery to the Brain via Nasal Route.” Journal of Controlled Release:
    Official Journal of the Controlled Release Society 189 (September): 133–40. https://doi.org/10.1016/j.jconrel.2014.06.053.
  32. Kulkarni, Abhijeet D., Yogesh H. Vanjari, Karan H. Sancheti, Veena S. Belgamwar, Sanjay J.
    Surana, and Chandrakantsing V. Pardeshi. 2015. “Nanotechnology-Mediated Nose to
    Brain Drug Delivery for Parkinson’s Disease: A Mini Review.” Journal of Drug Targeting
    23 (9): 775–88. https://doi.org/10.3109/1061186X.2015.1020809
  33. Kullmann, Stephanie, Martin Heni, Ralf Veit, Klaus Scheffler, Jürgen Machann, Hans
    Haring, Andreas Fritsche, and Hubert Preissl. 2017. “Intranasal Insulin Enhances Brain
    Functional Connectivity Mediating the Relationship between Adiposity and
    Subjective Feeling of Hunger.” Scientific Reports 7 (December). https://doi.org/10.1038/s41598-017-01907-w.
  34. Kullmann, Stephanie, Martin Heni, Ralf Veit, Klaus Scheffler, Jürgen Machann, Hans-
    Ulrich Häring, Andreas Fritsche, and Hubert Preissl. 2015. “Selective Insulin Resistance in
    Homeostatic and Cognitive Control Brain Areas in Overweight and Obese Adults.”
    Diabetes Care 38 (6): 1044–50. https://doi.org/10.2337/dc14-2319.
  35. Kullmann, Stephanie, Ralf Veit, Andreas Peter, Rolf Pohmann, Klaus Scheffler, Hans-Ulrich
    Häring, Andreas Fritsche, Hubert Preissl, and Martin Heni. 2018. “Dose-Dependent Effects
    of Intranasal Insulin on Resting-State Brain Activity.” The Journal of Clinical
    Endocrinology & Metabolism 103 (1): 253– 62. https://doi.org/10.1210/jc.2017-01976.
  36. Lange, Elizabeth Cm de. 2013. “The Mastermind Approach to CNS Drug Therapy:
    Translational Prediction of Human Brain
  37. Distribution, Target Site Kinetics, and Therapeutic Effects.” Fluids and Barriers of
    the CNS 10 (1): 12. https://doi.org/10.1186/2045-8118-10-12.
  38. Lioutas, Vasileios-Arsenios, Freddy Alfaro- Martinez, Francisco Bedoya, Chen-Chih
    Chung, Daniela A. Pimentel, and Vera Novak. 2015. “Intranasal Insulin and Insulin-Like
    Growth Factor 1 as Neuroprotectants in Acute Ischemic Stroke.” Translational Stroke
    Research 6 (4): 264–75. https://doi.org/10.1007/s12975-015-0409-7.
  39. Lochhead, Jeffrey J, Daniel J Wolak, Michelle E Pizzo, and Robert G Thorne. 2015. “Rapid
    Transport within Cerebral Perivascular Spaces Underlies Widespread Tracer Distribution in the Brain after Intranasal Administration.” Journal of Cerebral Blood Flow &
    Metabolism 35 (3): 371–81. https://doi.org/10.1038/jcbfm.2014.215.
  40. Mittal, Deepti, Asgar Ali, Shadab Md, Sanjula Baboota, Jasjeet K. Sahni, and Javed Ali. 2014. “Insights into Direct Nose to Brain Delivery: Current Status and Future Perspective.” Drug Delivery 21 (2): 75–86. https://doi.org/10.3109/10717544.2013.838713
  41. Novak, Vera, William Milberg, Ying Hao, Medha Munshi, Peter Novak, Andrew Galica, Bradley Manor, Paula Roberson, Suzanne Craft, and Amir Abduljalil. 2014. “Enhancement of Vasoreactivity andCognition by Intranasal Insulin in Type 2Diabetes.” Diabetes Care 37 (3): 751–59. https://doi.org/10.2337/dc13-1672.
  42. Oleck, Jacob, Shahista Kassam, and Jennifer D. Goldman. 2016. “Commentary: Why Was
    Inhaled Insulin a Failure in the Market?” Diabetes Spectrum 29 (3): 180–84. https://doi.org/10.2337/diaspect.29.3.180.
  43. Pardeshi, Chandrakantsing V., Pravin V. Rajput, Veena S. Belgamwar, Avinash R. Tekade, and
    Sanjay J. Surana. 2013. “Novel Surface Modified Solid Lipid Nanoparticles as
    Intranasal Carriers for Ropinirole Hydrochloride: Application of Factorial Design Approach.” Drug Delivery 20 (1): 47– 56. https://doi.org/10.3109/10717544.2012.752421.
  44. Reger, M. A., G. S. Watson, P. S. Green, C. W. Wilkinson, L. D. Baker, B. Cholerton, M. A.
    Fishel, et al. 2008. “Intranasal Insulin Improves Cognition and Modulates Beta-
    Amyloid in Early AD.” Neurology 70 (6): 440–48. https://doi.org/10.1212/01.WNL.0000265401. 62434.36.
  45. Ruigrok, Mitchel J. R., and Elizabeth C. M. de Lange. 2015. “Emerging Insights for
    Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans.” The AAPS Journal 17 (3): 493–505. https://doi.org/10.1208/s12248- 015-9724-x.
  46. Scherer, Thomas, Peter Wolf, Sabina Smajis, Melania Gaggini, Martina Hackl, Amalia
    Gastaldelli, Peter Klimek, et al. 2017. “Chronic Intranasal Insulin Does Not Affect Hepatic Lipids but Lowers Circulating BCAAs in Healthy Male Subjects.” Th Journal of Clinical Endocrinology and Metabolism 102 (4): 1325–32. https://doi.org/10.1210/jc.2016-3623.
  47. Schilling, Thomas M., Diana S. Ferreira de Sá, René Westerhausen, Florian Strelzyk, Mauro
    F. Larra, Manfred Hallschmid, Egemen Savaskan, et al. 2014. “Intranasal Insulin Increases Regional Cerebral Blood Flow in the Insular Cortex in Men Independently of Cortisol Manipulation.” Human Brain Mapping 35 (5): 1944–56. https://doi.org/10.1002/hbm.22304.
  48. Schmid, Vera, Stephanie Kullmann, Wieland Gfrörer, Verena Hund, Manfred Hallschmid, Hans-Peter Lipp, Hans-Ulrich Häring, Hubert Preissl, Andreas Fritsche, and Martin Heni. 2018. “Safety of Intranasal Human Insulin: A Review.” Diabetes, Obesity & Metabolism 20 (7): 1563–77. https://doi.org/10.1111/dom.13279.
  49. Selvaraj, Kousalya, Kuppusamy Gowthamarajan, and Veera Venkata Satyanarayana Reddy
    Karri. 2018. “Nose to Brain Transport Pathways an Overview: Potential of Nanostructured Lipid Carriers in Nose to Brain Targeting.” Artificial Cells, Nanomedicine, and Biotechnology 46 (8):
    2088–95. https://doi.org/10.1080/21691401.2017.14200 73.
  50. Shrewsbury, Stephen B., Maria Jeleva, Kelsey H. Satterly, Jason Lickliter, and John Hoekman.
    2019. “STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult Subjects.” Headache 59 (3): 394–409. https://doi.org/10.1111/head.13476.
  51. Stevens, Jasper, Bart A. Ploeger, Piet H. van der Graaf, Meindert Danhof, and Elizabeth C. M.
    de Lange. 2011. “Systemic and Direct Noseto- Brain Transport Pharmacokinetic Model for Remoxipride after Intravenous and Intranasal Administration.” Drug Metabolism and Disposition: The Biological Fate of Chemicals 39 (12): 2275–82. https://doi.org/10.1124/dmd.111.040782
  52. Stockhorst, U., D. de Fries, H.-J. Steingrueber, and W. A. Scherbaum. 2011. “Unconditioned and
    Conditioned Effects of Intranasally Administered Insulin vs Placebo in Healthy Men: A Randomised Controlled Trial.” Diabetologia 54 (6): 1502–6. https://doi.org/10.1007/s00125-011-2111-y.
  53. Teska, Brandon M., Javier Alarcón, Ronald J. Pettis, Theodore W. Randolph, and John F.
    Carpenter. 2014. “Effects of Phenol and Meta-Cresol Depletion on Insulin Analog Stability at Physiological Temperature.” Journal of Pharmaceutical Sciences 103 (8): 2255–67. https://doi.org/10.1002/jps.24039
  54. Thorne, R. G., L. R. Hanson, T. M. Ross, D. Tung, and W. H. Frey. 2008. “Delivery of
    Interferon-Beta to the Monkey Nervous System Following Intranasal Administration.” Neuroscience 152 (3): 785–97. https://doi.org/10.1016/j.neuroscience.2008.0 1.013.
  55. Thorne, R. G., G. J. Pronk, V. Padmanabhan, and W. H. Frey. 2004. “Delivery of Insulin-like
    Growth Factor-I to the Rat Brain and Spinal Cord along Olfactory and Trigeminal Pathways Following Intranasal Administration.” Neuroscience 127 (2): 481 96.https://doi.org/10.1016/j.neuroscience.2004.0 5.029.
  56. Wang, Dongxing, Yongliang Gao, and Liuhong Yun. 2006. “Study on Brain Targeting of
    Raltitrexed Following Intranasal Administration in Rats.” Cancer Chemotherapy and Pharmacology 57 (1): 97– 104. https://doi.org/10.1007/s00280-005- 0018-3.
  57. Warnken, Zachary N., Hugh D. C. Smyth, Daniel A. Davis, Steve Weitman, John G. Kuhn, and
    Robert O. Williams. 2018. “Personalized Medicine in Nasal Delivery: The Use of Patient-Specific Administration Parameters To Improve Nasal Drug Targeting Using 3DPrinted Nasal Replica Casts.” Molecular Pharmaceutics 15 (4): 1392–1402. https://doi.org/10.1021/acs.molpharmaceut.7b 00702.
  58. Warnken, Zachary N., Hugh D. C. Smyth, Alan B. Watts, Steve Weitman, John G. Kuhn, and
    Robert O. Williams. 2016. “Formulation and Device Design to Increase Nose to Brain
    Drug Delivery.” Journal of Drug Delivery Science and Technology 35 (October): 213–
    22. https://doi.org/10.1016/j.jddst.2016.05.003.
  59. Wheeler, Benjamin J, and Barry J Taylor. 2012. “Successful Management of Allergy to the
    Insulin Excipient Metacresol in a Child with Type 1 Diabetes: A Case Report.” Journal of
    Medical Case Reports 6 (1): 263. https://doi.org/10.1186/1752-1947-6-263
  60. Wingrove, Jed, Magda Swedrowska, Regina Scherließ, Mark Parry, Mervin Ramjeeawon, David Taylor, Gregoire Gauthier, et al. 2019. “Characterisation of Nasal Devices for Delivery of Insulin to the Brain and Evaluation in Humans Using Functional Magnetic Resonance Imaging.” Journal of Controlled Release 302 (May): 140–47. https://doi.org/10.1016/j.jconrel.2019.03.032.
  61. Wu, Hongbing, Kaili Hu, and Xinguo Jiang. 2008. “From Nose to Brain: Understanding
    Transport Capacity and Transport Rate of Drugs.” Expert Opinion on Drug Delivery 5 (10): 1159–68. https://doi.org/10.1517/17425247.5.10.1159
  62. Xiao, Changting, Satya Dash, Priska Stahel, and Gary F. Lewis. 2017. “Effects of Intranasal
    Insulin on Triglyceride-Rich Lipoprotein Particle Production in Healthy Men.” Arteriosclerosis, Thrombosis, and Vascular Biology 37 (9): 1776–81. https://doi.org/10.1161/ATVBAHA.117.3097
    05.
  63. Zhang, Hui, Ying Hao, Bradley Manor, Peter Novak, William Milberg, Jue Zhang, Jing
    Fang, and Vera Novak. 2015. “Intranasal Insulin Enhanced Resting-State Functional Connectivity of Hippocampal Regions in Type 2 Diabetes.” Diabetes 64 (3): 1025–34. https://doi.org/10.2337/db14-1000.